Great West Life Assurance Co. Can raised its holdings in TESARO Inc (NASDAQ:TSRO) by 16.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 11,213 shares of the biopharmaceutical company’s stock after buying an additional 1,593 shares during the period. Great West Life Assurance Co. Can’s holdings in TESARO were worth $1,385,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also added to or reduced their stakes in the company. TimesSquare Capital Management LLC bought a new position in shares of TESARO in the third quarter valued at $33,911,000. Tobam bought a new position in shares of TESARO in the second quarter valued at $20,189,000. Sphera Funds Management LTD. bought a new position in shares of TESARO in the second quarter valued at $7,692,000. Fiera Capital Corp bought a new position in shares of TESARO in the second quarter valued at $18,451,000. Finally, California State Teachers Retirement System lifted its stake in shares of TESARO by 20.8% in the second quarter. California State Teachers Retirement System now owns 68,090 shares of the biopharmaceutical company’s stock valued at $9,523,000 after buying an additional 11,706 shares in the last quarter.
Several analysts have recently commented on the stock. Robert W. Baird reiterated a “neutral” rating and issued a $125.00 target price on shares of TESARO in a report on Monday, October 2nd. Zacks Investment Research downgraded shares of TESARO from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. ValuEngine downgraded shares of TESARO from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. HC Wainwright assumed coverage on shares of TESARO in a report on Thursday, October 12th. They issued a “buy” rating and a $158.00 target price for the company. Finally, Piper Jaffray Companies reiterated a “neutral” rating and issued a $117.00 target price on shares of TESARO in a report on Monday, October 23rd. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $152.64.
TESARO Inc (NASDAQ TSRO) traded down $2.07 during midday trading on Friday, reaching $69.59. 1,741,081 shares of the company were exchanged, compared to its average volume of 871,867. TESARO Inc has a 1-year low of $69.38 and a 1-year high of $192.94. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.73 and a quick ratio of 4.35. The stock has a market capitalization of $3,897.01, a P/E ratio of -8.25 and a beta of 1.51.
TESARO (NASDAQ:TSRO) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.69. The business had revenue of $142.77 million during the quarter, compared to the consensus estimate of $130.57 million. TESARO had a negative net margin of 251.22% and a negative return on equity of 93.39%. The firm’s quarterly revenue was up 740.3% compared to the same quarter last year. During the same quarter last year, the company posted ($1.72) earnings per share. research analysts predict that TESARO Inc will post -8.19 earnings per share for the current fiscal year.
In other news, SVP Martin H. Jr. Huber sold 829 shares of TESARO stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $85.24, for a total value of $70,663.96. Following the completion of the transaction, the senior vice president now owns 8,101 shares in the company, valued at $690,529.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 40.50% of the stock is owned by company insiders.
TRADEMARK VIOLATION NOTICE: “TESARO Inc (NASDAQ:TSRO) Shares Bought by Great West Life Assurance Co. Can” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/01/13/tesaro-inc-tsro-shares-bought-by-great-west-life-assurance-co-can.html.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.